Virtus LifeSci Biotech Clinical Trials ETF (BBC) is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 138.3% from its 52-week low price of $13.42/share.Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed.BBC in FocusThe underlying LifeSci Biotechnology Clinical Trials Index is an equal weighted index that is designed to measure the equity market performanc ...